|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Grant income | ||||
| Operating income | ||||
| Research and development expenses | ||||
| General and administrative expenses | ||||
| Merger and listing expense | ||||
| Operating expenses | ||||
| Operating loss | ||||
| Finance income | ||||
| Finance expense | ||||
| Fair value adjustment on warrant liabilities | ||||
| Foreign currency exchange gain (loss) | ||||
| Finance result | ||||
| Loss before tax for the period | ||||
| Income tax benefit (expense) | ||||
| Loss for the period | ||||
| Loss per share [abstract] | ||||
| Basic, loss attributable to equity holders | ||||
| Diluted, loss attributable to equity holders |
Loading...
